Efficacy of multimodal anticancer therapy in the course of pancreatic neuroendocrine carcinoma

Not required for Clinical Vignette.

Bibliographic Details
Published in:	Endokrynologia Polska
Main Authors:	Helena Zwinczewska, Marta Opalinska, Anna Sowa-Staszczak, Anna Kurzynska, Agnieszka Stefanska, Alicja Hubalewska-Dydejczyk
Format:	Article
Language:	English
Published:	Via Medica 2021-04-01
Subjects:	neuroendocrine tumours PRRT pNEC somatostatin analogue
Online Access:	https://journals.viamedica.pl/endokrynologia_polska/article/view/72587

Similar Items

Predictive value of 68[Ga]Ga-DOTA-TATE PET/CT volumetric parameters in assessing treatment response to long-acting somatostatin analogues in patients with well-differentiated neuroendocrine tumours
by: Karolina Morawiec-Sławek, et al.
Published: (2024-11-01)

Small Bowel Neuroendocrine Tumors—10-Year Experience of the Ottawa Hospital (TOH)
by: Abdulhameed Alfagih, et al.
Published: (2023-08-01)

Clinical challenges and dilemmas in the management of advanced pancreatic neuroendocrine tumour — the first manifestation of von Hippel-Lindau disease in a young patient
by: Karolina Morawiec-Sławek, et al.
Published: (2021-08-01)

Paltusotine versus octreotide: different effects on radioligand uptake in neuroendocrine tumours
by: Katharina Wang, et al.
Published: (2025-10-01)

Neuroendocrine Tumours: a Literature Review
by: K. V. Menshikov, et al.
Published: (2021-05-01)

Satisfaction and quality of life in patients with symptomatic gastroenteropancreatic neuroendocrine tumours treated with lanreotide Autogel in South Africa
by: Daleen Geldenhuys, et al.
Published: (2020-10-01)

Current treatment options for gastroenteropancreatic neuroendocrine tumors with a focus on the role of lanreotide
by: Beata Kos-Kudła, et al.
Published: (2017-06-01)

The Crystal Structure Elucidation of a Tetrapeptide Analog of Somatostatin DOTA-Phe-D-Trp-Lys-Thr-OMe
by: Sabina Diusenova, et al.
Published: (2021-12-01)

Transcriptome of GH-producing pituitary neuroendocrine tumours and models are significantly affected by somatostatin analogues
by: Rihards Saksis, et al.
Published: (2023-02-01)

Quantitative and qualitative assessment of a pituitary neuroendocrine tumor’s T2-signal intensity in acromegaly – a call for unification
by: Magdalena Godlewska-Nowak, et al.
Published: (2024-11-01)

Intraoperative carcinoid syndrome during small-bowel neuroendocrine tumour surgery
by: Myrtille Fouché, et al.
Published: (2018-11-01)

A case report: enhanced somatostatin receptor expression in metastatic pancreatic neuroendocrine tumor following everolimus therapy
by: Pei Zhang, et al.
Published: (2025-10-01)

Predictive and Prognostic Impact of Blood-Based Inflammatory Biomarkers in Patients with Gastroenteropancreatic Neuroendocrine Tumors Commencing Peptide Receptor Radionuclide Therapy
by: Fiona Ohlendorf, et al.
Published: (2021-03-01)

Difficulties in the diagnosis and treatment of malignant paraganglioma of the urinary bladder
by: Ewelina Rzepka, et al.
Published: (2020-04-01)

Radioligand therapy (RLT) used to treat cardiac metastasis of pancreatic neuroendocrine tumor
by: Kieran J. Ved, et al.
Published: (2024-03-01)

Combination Therapies with PRRT
by: Anna Yordanova, et al.
Published: (2021-09-01)

The Clinico-epidemiologic Characteristics of Iraqi Patients with Neuroendocrine Tumors and Their Response to Long Acting Octreotide
by: Marwah K. Abdulfattah, et al.
Published: (2016-01-01)

Unmasking insulinoma following commencement of somatostatin analogues in malignant neuroendocrine tumours
by: Isuru Gamage, et al.
Published: (2025-07-01)

Determination of neuron-specific enolase in patients with midgut-type tumour treated with somatostatin analogues
by: Paweł Gut, et al.
Published: (2021-08-01)

Octreotide in the treatment of neuroendocrine carcinomas: Is the success achieved?
by: L. Yu. Morgunov
Published: (2015-06-01)

Chromogranin A: As A Tumor Marker for Neuroendocrine Tumors Diagnosis, Follow-up & Its Correlation with Response to Somatostatin Analogues
by: Manwar A. Mohammed AL-Naqqash
Published: (2016-01-01)

A head-to-head comparison between two commercial software packages for hybrid dosimetry after peptide receptor radionuclide therapy
by: Daphne M. V. Huizing, et al.
Published: (2020-06-01)

Emergency and routine presentation of neuroendocrine neoplasia in England: determinants of late presentation and survival outcomes
by: Marie Line El Asmar, et al.
Published: (2025-04-01)

Sunitinib in pancreatic neuroendocrine tumors. Clinical case
by: A. A. Markovich, et al.
Published: (2019-12-01)

Acromegaly and late-onset primary hyperparathyroidism in a female with a rare MEN1 gene variant of yet undetermined clinical significance (p.Val167Ala)
by: Magdalena Godlewska, et al.
Published: (2020-12-01)

Oligosymptomatic neuroendocrine neoplasm of the small intestine with metastases spread to the heart, bones, muscles and intraperitoneally after a few years in remission – diagnostic and therapeutic challenges
by: Natalia Tyrybon, et al.
Published: (2021-04-01)

Diagnostic imaging of gastrointestinal neuroendocrine neoplasms with a focus on ultrasound
by: Joanna Walczyk, et al.
Published: (2019-09-01)

Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms
by: Maria Isabel del Olmo-Garcia, et al.
Published: (2021-12-01)

A Care Process Model to Deliver 177Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors
by: Pashtoon Murtaza Kasi, et al.
Published: (2019-01-01)

“Cold” Somatostatin Analogs in Neuroendocrine Neoplasms: Decoding Mechanisms, Overcoming Resistance, and Shaping the Future of Therapy
by: Sara Massironi, et al.
Published: (2025-02-01)

Treatment Patterns of Pancreatic Neuroendocrine Tumor (pNET) Patients at Two Canadian Cancer Centres
by: Gautham Nair, et al.
Published: (2025-02-01)

Risk of treatment-altering haematological toxicity and its dependence on bone marrow doses in peptide receptor radionuclide therapy
by: Märta Persson, et al.
Published: (2024-02-01)

Pseudomyxoma Peritonei: Symptom Control and Objective Radiological Response after Treatment with Lanreotide Autogel
by: Gema Marín Zafra, et al.
Published: (2016-01-01)

Somatostatin Analogue Therapy in MEN1-Related Pancreatic Neuroendocrine Tumors from Evidence to Clinical Practice: A Systematic Review
by: Anna La Salvia, et al.
Published: (2021-10-01)

The role of serotonin inhibition within the treatment of carcinoid syndrome
by: Joel George, et al.
Published: (2023-06-01)

Treatments and Outcomes in Neuroendocrine Patients Treated with Long-Acting Somatostatin Analogues: An Italian Real-World Propensity Score-Matched Cohort Study
by: Nicoletta Ranallo, et al.
Published: (2025-02-01)

Radionuclide imaging and therapy in patients with neuroendocrine tumors
by: Olga D. Baranova, et al.
Published: (2018-03-01)

Primary Neuroendocrine Tumor of the Testis and Osseous, Cardiac, and Lymph Node Metastases in a Young Patient
by: Matthias Penke
Published: (2014-12-01)

Primary hepatic neuroendocrine tumor with multifocal liver involvement: A case report and review of the literature
by: Asmae Guennouni, PhD, et al.
Published: (2026-08-01)

Self-Administration of Long-Acting Somatostatin Analogues in NET Patients—Does It Affect the Clinical Outcome?
by: Anna Sowa-Staszczak, et al.
Published: (2021-11-01)